Metcalfe P, Watkins NA, Ouwehand WH et al. Nomenclature of human platelet antigens. Vox Sang 203;85:240-5.10.1046/j.1423-0410.2003.00331.x14516468Search in Google Scholar
Kiefel V, Santoso S, Weisheit M, Mueller-Eckhardt C. Monoclonal antibody-specific immobilization of platelet antigens (MAIPA): a new tool for the identification of platelet-reactive antibodies. Blood 1987;70:1722-6.10.1182/blood.V70.6.1722.1722Search in Google Scholar
Metcalfe P, Waters AH. HPA-1 typing by PCR amplification with sequence-specific primers (PCR- SSP): a rapid and simple technique. Br J Haematol 1993;85:227-9.10.1111/j.1365-2141.1993.tb08680.x8251400Search in Google Scholar
Jones DC, Bunce M, Fuggle SV, Young NT, Marshall SE. Human platelet alloantigens (HPAs): PCR-SSP genotyping of a UK population for 15 HPA alleles. Eur J Immunogenet 203;30:415-9.10.1111/j.1365-2370.2003.00426.x14675395Search in Google Scholar
Woods Jr VL, Kurata Y, Montgomery RR, et al. Autoantibodies against platelet glycoprotein Ib in patients with chronic immune thrombocytopenic purpura. Blood 1984a;64:156-60.10.1182/blood.V64.1.156.bloodjournal641156Search in Google Scholar
George JN, Raskob GE. Idiopathic thrombocytopenic purpura: a concise summar y of the pathophysiology and diagnosis in children and adults. Semin Hematol 1998;35:5-8.Search in Google Scholar
McMillan R. Therapy for adults with refractory chronic immune thrombocytopenic purpura. Ann Intern Med 1997;126:307-14.10.7326/0003-4819-126-4-199702150-000079036803Search in Google Scholar
Waters AH. Autoimmune thrombocytopenia: clinical aspects. Semin Hematol 1992;2:18-25.Search in Google Scholar
Lilleyman JS. Management of childhood idiopathic thrombocytopenic purpura. Br J Haematol 1999;105:871-5.10.1111/j.1365-2141.1999.01409.xSearch in Google Scholar
Zeller B, Helgestad J, Hellebostad M, et al. Immune thrombocytopenic purpura in childhood in Norway: a prospective, population-based registration. Pediatr Hematol Oncol 200;17:551-8.10.1080/0888001005012281611033730Search in Google Scholar
Kelton JG. The serological investigation of patients with autoimmune thrombocytopenia. Thromb Haemost 1995;74:228-33.10.1055/s-0038-1642682Search in Google Scholar
Warner MN, Moore JC, Warkentin TE, Santos AV, Kelton JG. A prospective study of protein-specific assays used to investigate idiopathic thrombocytopenic purpura. Br J Haematol 1999;104:442-7.10.1046/j.1365-2141.1999.01218.x10086776Search in Google Scholar
Provan D, Newland A, Norfolk D, et al. Guidelines for the investigation and management of idiopathic thrombocytopenic purpura in adults, children and in pregnancy. Br J Haematol 203;120:574-96.10.1046/j.1365-2141.2003.04131.xSearch in Google Scholar
Allen DL, Murphy MF. Evaluation of an enzyme- linked immunosorbent assay kit (GTI PakPlus) for the detection of antibodies against human platelet antigens. Transfus Med 1999;9:383-6.Search in Google Scholar
Williamson LM, Hackett G, Rennie J, et al. The natural history of fetomaternal alloimmunization to the platelet-specific antigen HPA-1a (P1A1, Zwa) as determined by antenatal screening. Blood 1998;92(7):2280-7.10.1182/blood.V92.7.2280Search in Google Scholar
Murphy MF,Verjee S, Greaves M. Inadequacies in the postnatal management of fetomaternal alloimmune thrombocytopenia. Br J Haematol 1999;105:123-6.Search in Google Scholar
Mueller-Eckhardt C, Kiefel V, Grubert A, et al. 348 cases of suspected neonatal alloimmune neonatal thrombocytopenia. Lancet 1989;1:363-6.10.1016/S0140-6736(89)91733-9Search in Google Scholar
Kaplan C, Morel-Kopp MC, Kroll H, et al. HPA-5b (Bra) neonatal alloimmune thrombocytopenia: clinical and immunological analysis of 39 cases. Br J Haematol 1991;78:425-9.10.1111/j.1365-2141.1991.tb04459.xSearch in Google Scholar
Décary F, L’Abbé D, Tremblay L, Chartrand P. The immune response to the HPA-1a antigen: association with HLA-DRw52a. Transfus Med 1991;1:55.10.1111/j.1365-3148.1991.tb00010.xSearch in Google Scholar
Kaplan C, Daffos F, Forestier F, Morel MC, Chesnel N, Tchernia G. Current trends in neonatal alloimmune thrombocytopenia: diagnosis and therapy. In: Kaplan-Gouet C, Schlegel N, Salmon Ch, Mcgregor J, eds. Platelet immunology: fundamental and clinical aspects. Paris: Colloque INSERM/John Libbey Eurotext, 1991;267-78.Search in Google Scholar
Spencer JA, Burrows RF. Feto-maternal alloimmune thrombocytopenia: a literature review and statistical analysis. Aust N Z J Obstet Gynaecol 201;41:45-55.10.1111/j.1479-828X.2001.tb01293.xSearch in Google Scholar
Murphy MF, Hambley H, Nicolaides K, Waters AH. Severe fetomaternal alloimmune thrombocytopenia presenting with fetal hydrocephalus. Prenat Diagn 1996;16:1152-5.10.1002/(SICI)1097-0223(199612)16:12<1152::AID-PD8>3.0.CO;2-JSearch in Google Scholar
Morel-Kopp MC, Daviet L, McGregor J, Kaplan C. Drawbacks of the MAIPA technique in characterising human antiplatelet antibodies. Blood Coagul Fibrinolysis, 1996;7:144-6.10.1097/00001721-199603000-00007Search in Google Scholar
Kroll H, Kiefel V, Santoso S. Clinical aspects and typing of platelet alloantigens. Vox Sang 1998;74(suppl 2):345-54.10.1111/j.1423-0410.1998.tb05441.xSearch in Google Scholar
Bessos H, Mirza S, McGill A,Williamson LM, Hadfield R, Murphy WG. A whole blood assay for platelet HPA1 (PlA1) phenotyping applicable to large-scale screening. Br J Haematol 1996;92:221-5.10.1046/j.1365-2141.1996.00290.xSearch in Google Scholar
Garner SF, Smethurst PA, Merieux Y, et al. A rapid one-stage whole-blood HPA-1a phenotyping assay using a recombinant monoclonal IgG1 anti-HPA-1a. Br J Haematol 200;108:440-7.10.1046/j.1365-2141.2000.01839.x10691879Search in Google Scholar
Ranasinghe E, Walton JD, Hurd CM, et al. Provision of platelet support for fetuses and neonates affected by severe fetomaternal alloimmune thrombocytopenia. Br J Haematol 201;113:40-2.10.1046/j.1365-2141.2001.02703.x11328278Search in Google Scholar
Adner MM, Fisch GR, Starobin SG, Aster RH. Use of compatible platelet transfusions in treatment of congenital isoimmune thrombocytopenic purpura. New Engl J Med 1969;280:244-7.10.1056/NEJM1969013028005055812507Search in Google Scholar
Mueller-Eckhardt C, Kiefel V, Grubert A. High dose IgG treatment for neonatal alloimmune thrombocytopenia. Blut 1989;59:145-6.10.1007/BF003202682752173Search in Google Scholar
Bussel JB, Zabusky MR, Berkowitz RL, McFarland JG. Fetal alloimmune thrombocytopenia. New Engl J Med 1997;337:22-6.10.1056/NEJM1997070333701049203427Search in Google Scholar
Engelfriet CP, Reesink HW, Kroll H, et al. International forum: Prenatal management of alloimmune thrombocytopenia. Vox Sang 203;84: 142-9.10.1046/j.1423-0410.2003.00269.x12609023Search in Google Scholar
Kroll H, Muntean W, Kiefel V, et al. Anti-Koa als ursache der neonatalen alloimmunthrombo- zytopenie. Beitr Infusionsther Transfusionsmed 1994;32:244-6.Search in Google Scholar
Kaplan C, Murphy MF, Kroll H, Waters AH. Fetomaternal alloimmune thrombocytopenia: antenatal therapy with IVIgG and steroids—more questions than answers. Br J Haematol 1998;100: 62-5.10.1046/j.1365-2141.1998.00533.x9450792Search in Google Scholar
Murphy MF,Waters AH, Doughty A, et al. Antenatal management of fetomaternal alloimmune thrombocytopenia—report of 15 affected pregnancies. Transfus Med 1994;4:281-92.10.1111/j.1365-3148.1994.tb00265.x7889140Search in Google Scholar
Birchall J, Murphy MF, Kaplan C, Kroll H. European collaborative study of the antenatal management of feto-maternal alloimmune thrombocytopenia. Br J Haematol 203;122:275-88.10.1046/j.1365-2141.2003.04408.x12846898Search in Google Scholar
Mackenzie F, Brennand J, Peterkin M, Cameron A. Management of fetal alloimmune thrombocyto- penia—a less invasive option? J Obstet Gynaecol 1999;19:119-21.10.1080/0144361996537215512247Search in Google Scholar
Radder CM, Brand A, Kanhai HHH. A less invasive treatment strategy to prevent intracranial hemorrhage in fetal and neonatal alloimmune thrombocytopenia. Am J Obstet Gynecol 201;185:683-8.10.1067/mob.2001.11672711568798Search in Google Scholar
Murphy MF, Williamson LM, Urbaniak SJ. Antenatal screening for fetomaternal alloimmune thrombocytopenia: should we be doing it? Vox Sang 202;83(Suppl.1):409-16.10.1111/j.1423-0410.2002.tb05343.x12617177Search in Google Scholar
van Loghem JJ, Dorfmeijer H, van der Hart M, Schreuder F. Serological and genetical studies on a platelet antigen (Zw). Vox Sang 1959;4:161–9.10.1159/000478465Search in Google Scholar
Shulman NR, Aster RH, Leitner A, Hiller MC. Immunoreactions involving platelets. V. Posttransfusion purpura due to a complement-fixing antibody against a genetically controlled platelet antigen. A proposed mechanism for thrombocytopenia and its relevance in ‘autoimmunity’. J Clin Invest 1961;40:1597–620.10.1172/JCI10438329085316695867Search in Google Scholar
Serious Hazards of Transfusion. Annual report 201–202. Serious hazards of transfusion scheme, Manchester, UK, 203. (www.shotuk.org).Search in Google Scholar
Watkins NA, Smethurst PA, Allen D, Smith GA, Ouwehand WH. Platelet alpha II beta 3 recombinant autoantibodies from the B-cell repertoire of a post-transfusion purpura patient. Br J Haematol 202;116:677-85.10.1046/j.0007-1048.2001.03301.x11849233Search in Google Scholar
Becker T, Panzer S, Maas D, et al. High-dose intravenous immunoglobulin for post-transfusion purpura. Br J Haematol 1985;61:149-55.10.1111/j.1365-2141.1985.tb04071.x4052323Search in Google Scholar
Slichter SJ. Controversies in platelet transfusion therapy. Annu Rev Med 1980;31:509-40.10.1146/annurev.me.31.020180.0024536994626Search in Google Scholar
British Committee for Standards in Haematology (203). Guidelines for the use of platelet transfusions. Br J Haematol 203;122:10-23.10.1046/j.1365-2141.2003.04468.x12823341Search in Google Scholar
Slichter SJ. Mechanisms and management of platelet refractoriness. In: Nance SJ, ed. Transfusion medicine in the 1990’s. Arlington, VA: American Association of Blood Banks, 1990:95-179.Search in Google Scholar
Bishop JF, McGrath K,Wolf MM,et al. Clinical factors inf luencing the efficacy of pooled platelet transfusions. Blood 1998;71:383-7.10.1182/blood.V71.2.383.383Search in Google Scholar
Doughty HA, Murphy MF, Metcalfe P, Rohatiner AZS, Lister TA, Waters AH. Relative importance of immune and non-immune causes of platelet refractoriness. Vox Sang 1994;66:200-5.10.1111/j.1423-0410.1994.tb00310.x8036790Search in Google Scholar
Delaflor-Weiss E, Mintz PD. The evaluation and management of platelet refractoriness and alloimmunisation. Transfus Med Rev 200;14: 180-96.10.1016/S0887-7963(00)80007-3Search in Google Scholar
The Trial to Reduce Alloimmunisation to Platelets Study Group. Leucocyte reduction and ultraviolet B irradiation of platelets to prevent alloimmunisation and refractoriness to platelet transfusions. New Eng J Med 1997;337:1861-9.10.1056/NEJM1997122533726019417523Search in Google Scholar
Murphy MF, Waters AH. Immunological aspects of platelet transfusions. Br J Haematol 1985;60: 409-14.10.1111/j.1365-2141.1985.tb07437.x4015986Search in Google Scholar
Kurz M, Greinix H, Hocker P, et al. Specificities of anti-platelets antibodies in multitransfused patients with hemato-oncological disorders. Br J Haematol 1996;95:564-9.10.1046/j.1365-2141.1996.d01-1936.x8943903Search in Google Scholar
Godeau B, Fromont P, Seror T, Duedari N, Bierling P. Platelet alloimmunisation after multiple transfusion: A prospective study of 50 patients. Br J Haematol 1992;81:395-400.10.1111/j.1365-2141.1992.tb08246.x1390213Search in Google Scholar
Meenaghan M, Judson PA, Yousaf K, Lewis L, Pamphilon DH. Antibodies to platelet glycoprotein V in polytransfused patients with hematological disease. Vox Sang 1993;64:167-70.10.1111/j.1423-0410.1993.tb05156.x8484249Search in Google Scholar
Kekomaki S, Volin L, Koistinen P, et al. Successful treatment of platelet transfusion refractoriness: The use of platelet transfusions matched for both human leukocyte antigens (HLA) and human platelet alloantigens (HPA) in alloimmunised patients with leukaemia. Eur J Haematol 1998;60:112-8.10.1111/j.1600-0609.1998.tb01007.x9508352Search in Google Scholar
Christie D J, Van Buren N, Lennon SS, Putman JL. Vancomycin-dependent antibodies associated with thrombocytopenia and refractoriness to platelet transfusion in patients with leukemia. Blood 1990;75:518-23.10.1182/blood.V75.2.518.518Search in Google Scholar
Warentin TE. Heparin-induced thrombocytopenia: pathogenesis and management. Br J Haematol 203;121:535-55.10.1046/j.1365-2141.2003.04334.x12752095Search in Google Scholar
Warkentin TE. Heparin-induced thrombocytopenia and thrombosis. Hematology 203. American Society of Hematology Education Program Book, 203;503-9.Search in Google Scholar
Campbell K, Garner SF, Hurd C, et al. Teicoplanin- dependent platelet antibodies as a cause of severe thrombocytopenia (abstract). J Thromb Haemost 203;1(suppl 1)OC024.Search in Google Scholar
